Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

Allen D. Brinker

Office of Drug Safety

Division of Drug Risk Evaluation

Center for Drug Evaluation and Research

U.S. Food and Drug Administration

USA

Name/email consistency: high

Office of Drug Safety, Division of Drug Risk Evaluation, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, USA. 2002 - 2005
Food and Drug Administration, Center for Drug Evaluation and Research, Office of Drug Safety, Rockville, USA. 2005

Patient characteristics associated with outpatient prescriptions for nabumetone and oxaprozin versus celecoxib and rofecoxib. Brinker, A., Nourjah, P. Am. J. Health. Syst. Pharm (2005) [Pubmed]
Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the accutane SMART program. Brinker, A., Kornegay, C., Nourjah, P. Arch. Dermatol (2005) [Pubmed]
Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin. Brinker, A., Goldkind, L., Bonnel, R., Beitz, J. Drugs. Aging (2004) [Pubmed]
Changes in ciprofloxacin utilization as shown in a large pharmacy claims database: effects of proximity to criminal anthrax exposure in October 2001. Brinker, A., Pamer, C., Beitz, J. J. Am. Pharm. Assoc. (2003) (2003) [Pubmed]
Spontaneous reports of thrombocytopenia in association with quinine: clinical attributes and timing related to regulatory action. Brinker, A.D., Beitz, J. Am. J. Hematol. (2002) [Pubmed]